Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) Eisai Co., Ltd.
Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021
ICARE AD-US is an observational real-world phase 4 study designed to evaluate the safety and effectiveness of ADUHELM in clinical practice ICARE AD-US is one of three programs to generate post-approval data on ADUHELM, including the re-dosing Phase 3b EMBARK study and the planned confirmatory Phase
Biogen and Ionis report positive topline clinical data on investigational Alzheimer’s disease treatment at AAIC
Phase 1b study of BIIB080/IONIS-MAPTRx met primary objective of safety and tolerability Study demonstrated durable, robust, time and dose dependent lowering of tau protein in cerebrospinal fluid CAMBRIDGE, Mass., and CARLSBAD, Calif., July 26, 2021 – Biogen. Inc.
Sustainability Report: 2020 Year in Review
Learn more about what actions we are taking to deliver on our bold and unwavering commitments to our patients, employees, environment and communities.